<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656367</url>
  </required_header>
  <id_info>
    <org_study_id>B346 (H-18024447)</org_study_id>
    <nct_id>NCT03656367</nct_id>
  </id_info>
  <brief_title>Designing Biofunctional Dairy Foods: Matrix Structure of Dairy Products in Relation to Lipaemia</brief_title>
  <acronym>DAIRYMAT</acronym>
  <official_title>Designing Biofunctional Dairy Foods: Matrix Structure of Dairy Products in Relation to Lipaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anne Birgitte Raben</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this study is to investigate how dairy products with different structures
      and textures affect lipid absorption kinetics in the acute postprandial period via blood
      lipid biochemistry.

      The study will be conducted as a randomized acute cross-over meal study. Apparently healthy
      men will be recruited in the study. They will on 4 test days consume the 4 dairy products and
      blood will be drawn the following 8 hours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aim of this study is to investigate how dairy products with similar nutrient
      content but different structures and textures affect lipid absorption kinetics in the acute
      postprandial period via blood lipid biochemistry, as well as nuclear magnetic resonance (NMR)
      and liquid chromatography mass spectrometry (LCMS)-based metabolomics.

      The study will be conducted as a randomized acute cross-over meal study. On four different
      test days (with a minimum of 2 weeks washout period) four dairy products with similar
      nutrient composition but different structures or textures will be tested. During each meal
      test a single dairy product (+ bread and water) is served and postprandial blood samples are
      collected the following 8 hours. Subjective appetite measurements (VAS) are filled in during
      the 8-hour period and an ad libitum meal is served in the end of the day.

      25 apparently healthy men (weight stable, 18-40 years, 18.5-24.9 kg/m2) will be recruited.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Actual">March 21, 2019</completion_date>
  <primary_completion_date type="Actual">March 21, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Due to the characteristics of the study design, blinding of project personnel and participants is not possible. However, statistical analyses of the results will be performed in a blinded fashion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>0-8 hour</time_frame>
    <description>The sample size is calculated on this endpoint. Fasting and postprandial concentrations of triglycerides (mmol/L) are measured after intake of a test meal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apolipoprotein B48</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Co-primary endpoint. Fasting and postprandial concentrations of apolipoprotein B48 are measured after intake of a test meal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cholesterol (total, LDL and HDL cholesterol)</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Fasting and postprandial concentrations of cholesterol (mmol/L) are measured after intake of a test meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Fatty Acid (FFA)</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Fasting and postprandial concentrations of FFA (umol/L) are measured after intake of a test meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Fasting and postprandial concentrations of insulin (pmol/L) are measured after intake of a test meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Fasting and postprandial concentrations of glucose (mmol/L) are measured after intake of a test meal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoproteins</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Fasting and postprandial concentrations of apolipoproteins (e.g. B100) are measured after intake of a test meal.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Paracetamol</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Gastric emptying rate is evaluated by paracetamol (measured as fasting and postprandial concentrations after intake of a test meal).</description>
  </other_outcome>
  <other_outcome>
    <measure>Metabolomics</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Detailed absorption kinetics will be evaluated by NMR-based metabolomics</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective appetite sensation</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Subjective appetite sensation (e.g. hunger, satiety, thirst) will be evaluated by visual analogue scales (VAS). The VAS is a line (100 mm in length) with words anchored at each end, expressing the most positive and the most negative rating of the subject's sensations. For example, Q: &quot;How hungry do you feel now?&quot;, rating: &quot;not at all&quot; (=0 mm) and &quot;extremely&quot; (=100 mm)</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute energy intake</measure>
    <time_frame>8 hours after test meal</time_frame>
    <description>Acute energy intake is evaluated by energy intake of an ad libitum meal that is served after the 8-hour test meal period</description>
  </other_outcome>
  <other_outcome>
    <measure>Appetite hormones</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Fasting and postprandial concentrations of appetite hormones (e.g. GLP-1) may be measured after intake of a test meal.</description>
  </other_outcome>
  <other_outcome>
    <measure>detailed metabolomics</measure>
    <time_frame>0-8 hour</time_frame>
    <description>Detailed absorption kinetics will be evaluated by LCMS-based metabolomics</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Lipaemia</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over study (all subjects receive all interventions)
Cheddar cheese
Blended and homogenized cheddar cheese
An analog milk
An analog cheese</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects only (subgroup)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If any subjects (against our hypothesis) have indices of metabolic syndrome i.e. raised fasting glucose or TG concentration, secondary analyses will be conducted to assess results without these subjects.
All subjects receive all interventions)
Cheddar cheese
Blended and homogenized cheddar cheese
An analog milk
An analog cheese</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cheddar cheese</intervention_name>
    <description>The reference product is a commercial matured cheddar cheese</description>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_label>Healthy subjects only (subgroup)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blended and homogenized cheddar cheese</intervention_name>
    <description>A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet</description>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_label>Healthy subjects only (subgroup)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>An analog milk</intervention_name>
    <description>An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network</description>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_label>Healthy subjects only (subgroup)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>An analog cheese</intervention_name>
    <description>This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference</description>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_label>Healthy subjects only (subgroup)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Apparently healthy men

          -  18-40 years of age

          -  Body mass index (BMI): 18.5-24.9 kg/m^2

          -  Non-smoker

          -  Haemoglobin concentration â‰¥8.4 mmol/L

        Exclusion Criteria:

          -  Dislike for dairy products such as milk, cheese and yoghurt

          -  Weight change &gt;3 kg 2 months prior to study

          -  Any other blood donation &lt; 3 month prior to study and during study, than the blood
             donation that is included in this study

          -  Intensive physical training (&gt;10 hours of per week)

          -  Self-reported eating disorders or irregular eating schedules (e.g. skipping breakfast)
             and uncommon diets (vegetarians, vegans etc.)

          -  Alcohol intake above the recommendation from the Danish Health and Medicines Authority
             (&gt;21 units of alcohol per week)

          -  Night- or shift work

          -  Food intolerance and allergies related to test products e.g. lactose and gluten

          -  Dietary supplements, if not taken on a regular basis

          -  Currently use, or use within previously 3 months of prescription medication, except
             non-prescription primary analgetica (NSAID and paracetamol) to relieve e.g. head ache
             and stomach pain, and glucocorticoider for topical use e.g. in ointment and creams.

          -  Chronic diseases e.g. cancer within the past 5 years (except adequately-treated
             localized basal cell skin cancer), asthma, back pain, thyroid disease, heart disease,
             diabetes, inflammation

          -  Disorders: neurological, sleep, diagnosed psychiatric disorder, and gastro intestinal
             and liver disorders.

          -  Surgical treatment of obesity and abdominal surgery

          -  Inability, physically or mental, to comply with the procedures required by the study
             protocol as evaluated by the daily study manager, principal investigator or clinical
             responsible

          -  Subject's general condition contraindicates continuing the study as evaluated by the
             daily study manager, principal investigator or clinical responsible

          -  Simultaneous participation in other clinical intervention studies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne B Raben, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nutrition, Exercise and Sports</name>
      <address>
        <city>Frederiksberg</city>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>June 21, 2019</last_update_submitted>
  <last_update_submitted_qc>June 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Anne Birgitte Raben</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>glycaemia</keyword>
  <keyword>insulinemia</keyword>
  <keyword>lipaemia</keyword>
  <keyword>appetite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

